Evaluate the Safety and Efficacy of Chimeric Antigen Receptor Engineered T Cell Immunotherapy (CAR-T) in the Treatment of Pancreatic Cancer in a Single Center, Non Controlled Clinical Study.
Phase of Trial: Phase 0
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Chimeric antigen receptor T cell therapeutics-Shanghai Youkadi Biomedical Technology (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 01 Sep 2017 New trial record